Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Marzia Del Re; Eleonora Rofi; Giuliana Restante; Stefania Crucitta; Elena Arrigoni; Stefano Fogli; Massimo Di Maio; Iacopo Petrini; Romano Danesi

doi:10.18632/oncotarget.23553

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini and Romano Danesi _

PDF | HTML | How to cite

Oncotarget. 2018; 9:6630-6643. https://doi.org/10.18632/oncotarget.23553

Metrics: PDF 3276 views | HTML 5085 views | ?

Abstract

Marzia Del Re1,*, Eleonora Rofi1,*, Giuliana Restante1, Stefania Crucitta1, Elena Arrigoni1, Stefano Fogli1, Massimo Di Maio2, Iacopo Petrini3 and Romano Danesi1

1Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

2Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy

3General Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

*These authors contributed equally to this work

Correspondence to:

Romano Danesi, email: [email protected]

Keywords: KRAS; NSCLC; treatment acquired resistance; TKI; pharmacogenetics

Received: September 06, 2017 Accepted: October 27, 2017 Published: December 21, 2017

ABSTRACT

Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies.

The focus of this review will be to provide an overview of the network related to the intricate molecular KRAS pathways, stressing on preclinical and clinical studies that investigate the predictive value of KRAS mutations in NSCLC patients.

Materials and Methods: A bibliographic search of the Medline database was conducted for articles published in English, with the keywords KRAS, KRAS mutations in non-small cell lung cancer, KRAS and tumorigenesis, KRAS and TKIs, KRAS and chemotherapy, KRAS and monoclonal antibody, KRAS and immunotherapy, KRAS and drugs, KRAS and drug resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23553

Publication Alerts

Reviews:

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Abstract